Home » Posts tagged 'medical imaging.' (Page 2)
Tag Archives: medical imaging.
Feedback (FDBK) raises £200,000 to fund TexRAD development
Feedback plc (FDBK), the medical imaging software company, is pleased to announce that it has placed 11,111,111 new ordinary shares of 0.25 pence each at a price of 1.8 pence per ordinary share with a number of existing and new investors raising £200,000. The Placing has been completed by Peterhouse Corporate Finance Limited.
The proceeds of the Placing will fund continuing development of the TexRAD software.
The Placing includes participation by two of Feedback’s directors, Tom Charlton who invested £50,400 for 2,800,000 Placing Shares and Trevor Brown who invested £18,000 for 1,000,000 Placing Shares both at a price of 1.8 pence per ordinary share. Following the Placing, the Participating Directors will be interested in a total of 104,613,919 ordinary shares in the Company representing 51.83% of the enlarged issued share capital of the Company. The shareholdings of the Participating Directors on completion of the Placing will be as follows:
| Director | No. of Shares | % |
| Trevor Brown | 55,089,111 | 27.29 |
| Tom Charlton | 49,524,808 | 24.53 |
The Placing Shares will rank pari passu with the existing Ordinary Shares and application will be made for the Placing Shares to be admitted to trading on AIM. It is expected that Admission will become effective and dealings in the Placing Shares will commence by 8.00 a.m. on 8 June 2015.
Following Admission of the Placing Shares, the Company’s enlarged issued share capital will consist of 201,857,857 ordinary shares with voting rights. This number may be used by shareholders, following the Placing, as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules.
Related Party Transaction:
Due to the fact that Trevor Brown and Tom Charlton are directors of the Company and the size of their respective shareholdings, their participation in the Placing constitutes a related party transaction as defined in the AIM Rules. Simon Barrell, Non-Executive Chairman, has not participated in the Placing and is therefore deemed to be independent under the AIM Rules for the purposes of considering the related party transaction. The Independent Director, having consulted with Sanlam Securities UK Limited, the Company’s nominated adviser, considers that the terms of the participation in the Placing by the Participating Directors are fair and reasonable insofar as the Company’s shareholders are concerned.
For further information please contact:
| Feedback plc | Tel: 01954 718072 |
| Simon Barrell / Trevor Brown / Tom Charlton
|
|
| Sanlam Securities UK (Nominated Adviser and Joint Broker) | Tel: 020 7628 2200 |
| Simon Clements / Virginia Bull/ Andrew Wagstaff
|
|
| Peterhouse Corporate Finance Ltd (Joint Broker) | Tel: 020 7469 0936 |
| Lucy Williams / Duncan Vasey |
Medical Imaging News – Stainless staining provides a new tool for clinicians and researchers
Medical Imaging News – Stainless staining provides a new tool for clinicians and researchers
Science News from World Scientific
Histopathology is a cornerstone of modern biomedical research. Yet, the practice of histopathology has evolved just a few times — non-specific stains in the late 19th century, immunohistochemical staining in the mid-to-late 20th century and digital imaging/computerized analysis at the turn of the 20th century. In all cases, prepared biopsy samples are stained and examined under a light microscope. This study reports a new approach to histology in which a team of engineers, pathologists and surgeon report the development of label-free chemical imaging to provide the same information as molecular stains. Led by Rohit Bhargava at the University of Illinois, the study is based on using infrared spectroscopic imaging for microscopy.
Instead of using stains, the spectra measure the chemical constitution of cells and tissues directly. By using computational techniques, the researchers were able to relate spectral properties to known staining patterns of tissue. The outcome is that that molecular stains can be reproduced without staining the tissue but by using the intrinsic molecular contrast of the tissue and computation. Thus, any sample can be stained for desired stains without material cost, time or effort while leaving precious tissue pristine for downstream analyses. Another use of the approach can be in the analysis of small amounts of samples, for example from a thin needle biopsy. In cases where materials are limited or there may be a need to closely correlate multiple expressed molecules, it may not be possible to obtain multiple samples from the same biopsy for multiple stains. The method developed in this study could be a solution, allowing the user to simply “dial-in” a required stain. The study is timely as it builds on the emergence of chemical imaging and maturation of computation from the sciences/engineering side and the drive to greater molecular content from the biomedical/clinical side.
Link here for full article
Alan Green gives good Feedback on Feedback PLC with Justin Waite on the ADVFN podcast
Alan Green gives good Feedback on Feedback PLC with Justin Waite on the ADVFN podcast.
Medical Imaging News – Susceptibility Weighted Imaging in the Evaluation of Cerebrovascular Hemodynamics
By Carlos Zamora – Guest Editor – American Journal of Neuroradiology News Digest
Susceptibility-weighted imaging (SWI) is a high-resolution, fully velocity-compensated gradient-echo MRI sequence that maximizes intrinsic contrast differences between tissues by virtue of their local magnetic properties. This technique exploits susceptibility information contained within phase acquisitions and merges such with magnitude data to generate a clinically usable set of images.
Notably, the functional incorporation of phase data in a clinical sequence was initially challenging and warranted improvements in MRI technology that eventually culminated in the development of SWI. The entire sequence requires no more than a few minutes of scanning time and can be effectively applied in a clinical setting.
Link here to full article
Feedback announces a new drug trial and provides a trading update
Feedback plc notes that TexRAD, its texture analysis software product will be used by Imaging Endpoints II, LLC, its exclusive partner, for imaging core lab purposes in a forthcoming drug trial in the United States. A study will shortly be commenced of colorectal cancer patients (Stage IIIc) with either Regorafenib or Standard of Care (No Treatment) after adjuvant FOLFOX. The Sponsor is US Oncology Research and the Collaborator is Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma.
Trading Update
Following the recent announcements of new sales of TexRAD, the Company announces an update on current trading.
Revenue for the current financial year ending May 2015 is expected to be in line with market expectations however due to contractual settlement costs, the product sales mix and the timing of the revenue recognition from the new TexRAD sales, the loss for the year will be higher than the current market expectations.
We continue to seek to broaden the Company’s profile in the medical imaging software sector and are in active discussions with a number of potential customers for research versions of the TexRad product.
We continue to manage our limited working Replica capital resources so as to maximise opportunities with customers and also to continue to develop the Disaster Company’s products.
Feedback announces a collaboration with Princess Alexandra Hospital, Brisbane, AU
Feedback plc is pleased to announce that it is undertaking a study cheap mlb jerseys using wholesale nfl jerseys its TexRAD research product with the Diagnostic Radiology department at the Princess Alexandra Hospital in Brisbane, Australia to assess the potential for clinical workflow integration for TexRAD quantitative computed tomography specifically focused on Минска non-small cell lung cancer.
The study will be led by Prof. Ken Miles (Senior Medical Officer in the Diagnostic Radiology department of PAH). Prof. Miles is also a Professorial Research Associate in the Institute of Flipster Nuclear Medicine, University College London, UK. Prof. Miles has an international reputation in functional imaging of tumours, ranging from the development of new techniques through St, to demonstrating cost-effectiveness. For example he has been one of the pioneers of CT perfusion (blood-flow) and CT texture (heterogeneity) analysis technologies.
Prof. Ken Miles commented: “TexRAD as research software has been used to Normal investigate lung cancer on CT where it has been shown to be associated with underlying tumour biology and has the Graphics potential to be an independent prognostic marker. Preliminary studies TexRAD have also demonstrated potential clinical applications for TexRAD analysis to assist treatment decisions and optimise lung cancer patient management in a cost-effective manner. We hope this study will demonstrate that TexRAD could be incorporated into the routine radiological workflow.”
Dr. Balaji Ganeshan, Chief Scientist & New Business Officer of the Company’s subsidiaries TexRAD Ltd & Cambridge Computed Imaging Ltd commented: “Prof. Ken Miles is one of the top functional imaging academics, dual wholesale nfl jerseys trained in radiology and nuclear medicine and we are delighted that he will be leading the very first landmark study in evaluating potential clinical implementation with our TexRAD software focused on lung cancer. Working with Princess Alexandra Hospital in Brisbane will Barclays enhance our TexRAD research cheap nba jerseys collaborator base with the addition of a key site in this new geographical region.”